会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明公开
    • 란소프라졸 결정형 A의 제조방법
    • 制备兰索唑晶型的方法
    • KR1020070073419A
    • 2007-07-10
    • KR1020060001303
    • 2006-01-05
    • 주식회사 대웅제약대웅바이오 주식회사
    • 문성철송인웅강두성오성수이성재
    • C07D401/12
    • C07D401/12
    • A method for preparing crystalline form A of lasnoprazole is provided to mass-produce the crystalline form A of lasnoprazole with high purity without a separate converting step from an ethanol solvent by adjusting the temperature and agitation time required for crystallization. The method comprises the steps of: (a) after dissolving 1 part by weight of lansoprazole obtained by oxidizing 2-([3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]-methyl)thio-1H-benzimidazole in 1-50 parts by weight of ethanol, adding water thereto; (b) agitating the product obtained from the step(a) at a temperature of 15-40 deg.C for 0.5-4 hours; and (c) filtering and drying the product obtained from the step(b). Before adding the water, the color of the solution is removed by using charcoal and Na2S2O4.
    • 提供了一种制备拉唑诺唑结晶A的方法,通过调节结晶所需的温度和搅拌时间,大量生产高纯度的拉诺拉唑的结晶形式A,而无需通过乙醇溶剂的单独转化步骤。 该方法包括以下步骤:(a)将1 - ((3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基] - 甲基)硫代 - 1-苯并咪唑在1-50重量份乙醇中,向其中加入水; (b)在15-40℃的温度下搅拌从步骤(a)获得的产物0.5-4小时; 和(c)过滤并干燥由步骤(b)获得的产物。 加入水之前,用炭和Na2S2O4去除溶液的颜色。
    • 7. 发明公开
    • 코엔자임 Qn의 제조방법 및 그의 중간체
    • 制备聚苯乙烯QN及其中间体的方法
    • KR1020060117430A
    • 2006-11-17
    • KR1020050038841
    • 2005-05-10
    • 주식회사 대웅제약대웅바이오 주식회사
    • 최수진박준석문성철오성수김태이임영묵이성재최승섭이한국이병구이봉용
    • C07C46/02C07C46/06
    • A process for preparing a coenzyme Qn is provided to simplify the processing steps, to allow use of mild reaction conditions, and to improve the yield and purity of a coenzyme Qn useful as an active ingredient of health-aid foods or pharmaceuticals. The process for preparing a coenzyme Qn comprises the steps of: reacting a compound represented by the following formula 5 with a compound represented by the following formula 6 in the presence of a base to provide a compound represented by the formula 7; subjecting the compound represented by the formula 7 to desulfonation and deprotection under an acidic condition to provide a compound represented by the following formula 8; and carrying out oxidation of the compound represented by the formula 8 by using at least one oxidant selected from the group consisting of FeCl3, FeCl3À6H2O, CuCl2, CuCl2À2H2O, MnO2 and NaOCl to obtain a compound represented by the following formula 1. In the above formulae, n is an integer of 2-12; each of R2 and R3 is a C1-C4 alkyl or alkoxy, or R2 and R3 may form a benzene ring together with the carbon atom to which they are attached; R4 is a halogen-substituted or non-substituted C1-C4 alkyl or nitro-substituted or non-substituted C6-C10 aromatic hydrocarbon: R5 is tetrahydropyranyl, 1-ethoxyethyl or tetrahydrofuranyl; and Y is a halogen atom.
    • 提供了一种制备辅酶Q n的方法,以简化加工步骤,允许使用温和的反应条件,并提高可用作健康助剂食品或药物的有效成分的辅酶Qn的产率和纯度。 制备辅酶Q n的方法包括以下步骤:使由下式5表示的化合物与下式6表示的化合物在碱的存在下反应,得到式7表示的化合物; 使式7表示的化合物在酸性条件下进行脱磺化和脱保护,得到由下式8表示的化合物; 并使用选自FeCl 3,FeCl 3·6H 2 O,CuCl 2,CuCl 2·2H 2 O,MnO 2和NaOCl中的至少一种氧化剂进行由式8表示的化合物的氧化,得到由下式1表示的化合物。在上述式 ,n为2〜12的整数。 R 2和R 3各自为C 1 -C 4烷基或烷氧基,或者R 2和R 3可与它们所连接的碳原子一起形成苯环; R4是卤素取代或未取代的C1-C4烷基或硝基取代或未取代的C6-C10芳族烃:R5是四氢吡喃基,1-乙氧基乙基或四氢呋喃基; Y为卤素原子。
    • 9. 发明授权
    • 케노데옥시콜린산의 정제 방법
    • 케노데옥시콜린산의정제방법
    • KR100658512B1
    • 2006-12-19
    • KR1020050134837
    • 2005-12-30
    • 주식회사 대웅제약
    • 김태이김영수임영묵김월영윤연정진용석이병구최수진이성재
    • C07H21/00C07C51/42
    • A process for purifying chenodeoxycholic acid is provided to reduce the purification time and improve purification yield and purity by pretreating solid porcine gall with organic solvent and crystallizing acetylated bile acid ester under mild temperature. The process for purifying chenodeoxycholic acid represented by the formula(1) comprises the steps of: dissolving solid porcine gall containing 35-55% of chenodeoxycholic acid in organic solvent containing salts; esterifying the bile acid; acetylating the bile acid ester; removing intermediates by using nonpolar organic solvent; crystallizing the acetylated bile acid ester with C1-C4 alcohol at 15-25 deg. C; and deprotecting the crystallized product by adding a base into the crystallized product and crystallizing it in the presence of water by adding water at 35-45 deg. C, wherein the salt used in the pretreatment is sodium chloride, anhydrous magnesium sulfate or anhydrous sodium sulfate.
    • 本发明提供了一种纯化鹅脱氧胆酸的方法,通过在有机溶剂中预处理固体猪胆和在温和温度下结晶乙酰化胆汁酸酯来缩短纯化时间并提高纯化产率和纯度。 由式(1)表示的用于纯化鹅脱氧胆酸的方法包括以下步骤:将含有35-55%鹅脱氧胆酸的固体猪胆溶解在含有盐的有机溶剂中; 酯化胆汁酸; 乙酰化胆汁酸酯; 用非极性有机溶剂除去中间体; 在15-25℃下用C 1 -C 4醇使乙酰化胆汁酸酯结晶。 C; 并通过向结晶产物中加入碱并在水存在下通过加入35-45℃的水使其结晶来将结晶产物脱保护。 其中用于预处理的盐是氯化钠,无水硫酸镁或无水硫酸钠。